ArticleNPJ Parkinson's disease2022
Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson's disease phenotypes.
Article in NPJ Parkinson's disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 24 citations in OpenAlex.
- Evaluating the Role of α-Synuclein Seed Amplification as a Disease Progression Marker: Evidence and Uncertainties.Movement disorders clinical practice · 2026Article
- A Holistic and Dynamic Network-Level View of the Autonomic Nervous System.Annual review of biomedical engineering · 2026Review
- Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder.Signal transduction and targeted therapy · 2026Article
- Faster reaction times of CSF alpha-synuclein seed amplification assay predict the diffuse malignant subtype of Parkinson's disease at 10-year follow-up.Journal of Parkinson's disease · 2026Article
- Faster reaction times of CSF Alpha-Synuclein Seed Amplification Assay predict the Diffuse Malignant subtype of Parkinson's Disease at 10-year follow-up.medRxiv : the preprint server for health sciences · 2025Article
- Should old acquaintance be forgot: A call for recognition and inclusion of advanced Parkinson's disease patients & care partners in evolving research models.Parkinsonism & related disorders · 2025Article
- New diagnostic and staging framework applied to established PD in the BioFIND cohort.NPJ Parkinson's disease · 2025Article
- Can the Pupillary Light Reflex and Pupillary Unrest Be Used as Biomarkers of Parkinson's Disease? A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Clinical features, plasma neurotransmitter levels and plasma neurohormone levels among patients with early-stage Parkinson's disease with sleep disorders.Cell communication and signaling : CCS · 2025Article
- Association between the Amplification Parameters of the α-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis.Nature reviews. Neurology · 2024Review
- Predictors for early-onset psychotic symptoms in patients newly diagnosed with Parkinson's disease without psychosis at baseline: A 5-year cohort study.CNS neuroscience & therapeutics · 2024Article
- Emerging wearable technologies for multisystem monitoring and treatment of Parkinson's disease: a narrative review.Frontiers in network physiology · 2024Review
- Interactive effect of orthostatic hypotension on gray matter atrophy associated with hyposmia and RBD in de novo Parkinson's disease.Journal of neurology · 2023Article
- Serum but not cerebrospinal fluid levels of allantoin are increased in de novo Parkinson's disease.NPJ Parkinson's disease · 2023Article
- Factors contributing to sleep disturbances and excessive daytime sleepiness in patients with Parkinson's disease.Frontiers in neurology · 2023Article
- Epidemiology of autonomic dysfunction in Parkinson's disease (Review).Medicine internationalReview
- Associations of non-motor symptoms with perceptual speech impairments in Parkinson's disease.Frontiers in neurologyArticle
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Non-motor symptoms of Parkinson's disease (PD) such as dysautonomia and REM sleep behavior disorder (RBD) are recognized to be important prodromal symptoms that may also indicate clinical subtypes of PD with different pathogenesis. Unbiased clustering analyses showed that subjects with dysautonomia and RBD symptoms, as well as early cognitive dysfunction, have faster progression of the disease. Through analysis of the Parkinson's Progression Markers Initiative (PPMI) de novo PD cohort, we tested the hypothesis that symptoms of dysautonomia and RBD, which are readily assessed by standard questionnaires in an ambulatory care setting, may help to independently prognosticate disease progression. Although these two symptoms associate closely, dysautonomia symptoms predict severe progression of motor and non-motor symptoms better than RBD symptoms across the 3-year follow-up period. Autonomic system involvement has not received as much attention and may be important to consider for stratification of subjects for clinical trials and for counseling patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.